We are monitoring the impact of COVID-19 on Checkpoint Inhibitors Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 2084
Share on
Share on

Global Checkpoint Inhibitors Market Analysis – By Type (PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell and others), Application (Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others), Region - Industry Size, Share, Trends, Forecast, Growth | 2019 - 2024

Pulished: August, 2019
ID: 2084
Pages: 175

Global Checkpoint Inhibitors Market Size & Growth (2019 - 2024)

The size of the Global Checkpoint Inhibitors Market was valued at USD 12.9 billion in 2019 and is expected to reach USD 45.4 billion by 2024 with a CAGR of 28.68 % during the forecast period 2019 - 2024.

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launch an attack when it detects infected or Cancerous. The immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on cancer cells.

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the Checkpoint Inhibitors Market.

Some of the other prominent factors that drive the growth of the global checkpoint inhibitors market are the increase in funds, support from the government in developing new drugs and frequent rise in cancer. Precision in medicine will be a major driver for pharmaceuticals to deliver innovative medicines. There is an extreme force of competition in checkpoint inhibitors, which is driving the learning or developing skill and in-license agreements. This is also driven by research developments made by learning institutes and industry contributors. By affecting the cost of the nation, there is a need to address the day to day increase of cancer prevalence.

A comprehensive analysis of regions is to provide the current opportunities. It also offers a quantitative study to enable the stakeholders to make a massive amount in market opportunities.

The high cost that is involved in research and development is one of the major factors restraining from the global checkpoint inhibitors market. In addition, the lack of awareness and proper publicity for the use of these inhibitors, especially in the developing regions, are also acting as deterrents for the expansion of the global checkpoint inhibitors market.

Recent Developments

  • In February 2019, Merck & Co., Inc. has announced that they had received US FDA approval for the checkpoint inhibitor “Keytruda”, which is used for the treatment of Merkel cell carcinoma.
  • For the treatment of non-small cell lung cancer in advanced stages, the F. Hoffmann-La Roche Ltd. announced in January 2019 that they received US FDA approval for “Tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin.
  • In October 2018, for the treatment of advanced cutaneous squamous cell carcinoma, The Regeneron announced that they had received US FDA approval for “Libtayo”.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 – 2024

Segments Analysed

By Drug, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Analysed

Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma

 

This research report on the Global Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.

Checkpoint Inhibitors Market Analysis - By Drug:

  • PD-1 inhibitors
  • PD-L1 inhibitors
  • CTLA-4
  • Chimeric Antigen Receptor T-cell
  • Others

On the basis of drugs, the CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market share to the PD-1 inhibitors segment during the forecast period as the majority of new treatments are based on PD-1 inhibitors.

Checkpoint Inhibitors Market Analysis - By Application:

  • Lung Cancer
  • Renal Cancer
  • Blood Cancer
  • Bladder Cancer
  • Hodgkin Lymphoma
  • Melanoma
  • Others

Regional Analysis:

North America dominates the global checkpoint inhibitors market, owing to high clinics and also the availability of funds. But, APAC, i.e., Asia-Pacific is the fastest-growing region. In this region, international players collaborate with local companies. Asia-Pacific produces a great deal of profit for the key players, who are operating in the immune checkpoint inhibitors market, which is supported by its large population and their awareness about the immune therapy, etc. 

Latin America and Middle East & Africa are also expected to produce a great deal of profit for the key players during the forecast period. Due to the development in healthcare, there will be a rise in demand for checkpoint inhibitors market in all parts of the world.

Key market participants leading the Global Checkpoint Inhibitors Market profiled in the report are:

  1. Merck & Co. Inc.
  2. Bristol-Myers Squibb
  3. Roche
  4. AstraZeneca
  5. Ono Pharmaceutical Co., Ltd
  6. Juno Therapeutics
  7. Novartis International AG
  8. Kite Pharma

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 PD-1 inhibitors       

                                5.1.3 PD-L1 inhibitors     

                                5.1.4 CTLA-4      

                                5.1.5  Chimeric Antigen Receptor T-cell 

                                5.1.6  Others     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type           

                                5.1.8 Market Attractiveness Analysis, By Drug Type         

                                5.1.9 Market Share Analysis, By Drug Type          

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Lung cancer            

                                5.2.3 Renal cancer           

                                5.2.4 Blood cancer          

                                5.2.5 Bladder Cancer      

                                5.2.6  Hodgkin lymphoma            

                                5.2.7 Melanoma              

                                5.2.8  Others     

                                5.2.9 Y-o-Y Growth Analysis, By Application         

                                5.2.10  Market Attractiveness Analysis, By Application   

                                5.2.11  Market Share Analysis, By Application     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                                6.1.3.3 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                                6.1.4.3 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Type

                                                6.1.5.3 By Application

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Merck & Co., Inc.                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 Roche                           

                8.4 AstraZeneca                               

                8.5 Ono Pharmaceutical Co., Ltd.                              

                8.6  Juno Therapeutics                  

                8.7 Novartis International AG                    

                8.8 Kite Pharma                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Checkpoint Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  2. Global Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  3. Global PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  4. Global PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  5. Global CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  6. Global Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  7. Global Others Market By Region, From 2019-2024 ( USD Billion )
  8. Global Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  9. Global Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  10. Global Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  11. Global Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  12. Global Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  13. Global Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  14. Global Melanoma Market By Region, From 2019-2024 ( USD Billion )
  15. Global Others Market By Region, From 2019-2024 ( USD Billion )
  16. North America Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  17. North America PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  18. North America PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  19. North America CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  20. North America Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  21. North America Others Market By Region, From 2019-2024 ( USD Billion )
  22. North America Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  23. North America Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  24. North America Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  25. North America Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  26. North America Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  27. North America Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  28. North America Melanoma Market By Region, From 2019-2024 ( USD Billion )
  29. North America Others Market By Region, From 2019-2024 ( USD Billion )
  30. United States Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  31. United States Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  32. Canada Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  33. Canada Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  34. Europe Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  35. Europe PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  36. Europe PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  37. Europe CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  38. Europe Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  39. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  40. Europe Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  41. Europe Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  42. Europe Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  43. Europe Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  44. Europe Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  45. Europe Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  46. Europe Melanoma Market By Region, From 2019-2024 ( USD Billion )
  47. Europe Others Market By Region, From 2019-2024 ( USD Billion )
  48. U.K. Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  49. U.K. Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  50. Germany Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  51. Germany Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  52. France Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  53. France Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  54. Italy Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  55. Italy Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  56. Spain Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  57. Spain Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  58. Asia-Pacific Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  59. Asia-Pacific PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  60. Asia-Pacific PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  61. Asia-Pacific CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  62. Asia-Pacific Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  63. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  64. Asia-Pacific Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  65. Asia-Pacific Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  66. Asia-Pacific Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  67. Asia-Pacific Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  68. Asia-Pacific Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  69. Asia-Pacific Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  70. Asia-Pacific Melanoma Market By Region, From 2019-2024 ( USD Billion )
  71. Asia-Pacific Others Market By Region, From 2019-2024 ( USD Billion )
  72. Japan Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  73. Japan Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  74. China Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  75. China Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  76. India Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  77. India Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  78. Australia Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  79. Australia Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  80. South Korea Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  81. South Korea Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  82. Latin America Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  83. Latin America PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  84. Latin America PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  85. Latin America CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  86. Latin America Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  87. Latin America Others Market By Region, From 2019-2024 ( USD Billion )
  88. Latin America Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  89. Latin America Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  90. Latin America Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  91. Latin America Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  92. Latin America Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  93. Latin America Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  94. Latin America Melanoma Market By Region, From 2019-2024 ( USD Billion )
  95. Latin America Others Market By Region, From 2019-2024 ( USD Billion )
  96. Brazil Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  97. Brazil Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  98. Argentina Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  99. Argentina Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  100. Mexico Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  101. Mexico Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  102. Rest of Latin America Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  103. Rest of Latin America Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  104. Middle East & Africa Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  105. Middle East & Africa PD-1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  106. Middle East & Africa PD-L1 inhibitors Market By Region, From 2019-2024 ( USD Billion )
  107. Middle East & Africa CTLA-4 Market By Region, From 2019-2024 ( USD Billion )
  108. Middle East & Africa Chimeric Antigen Receptor T-cell Market By Region, From 2019-2024 ( USD Billion )
  109. Middle East & Africa Others Market By Region, From 2019-2024 ( USD Billion )
  110. Middle East & Africa Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  111. Middle East & Africa Lung cancer Market By Region, From 2019-2024 ( USD Billion )
  112. Middle East & Africa Renal cancer Market By Region, From 2019-2024 ( USD Billion )
  113. Middle East & Africa Blood cancer Market By Region, From 2019-2024 ( USD Billion )
  114. Middle East & Africa Bladder Cancer Market By Region, From 2019-2024 ( USD Billion )
  115. Middle East & Africa Hodgkin lymphoma Market By Region, From 2019-2024 ( USD Billion )
  116. Middle East & Africa Melanoma Market By Region, From 2019-2024 ( USD Billion )
  117. Middle East & Africa Others Market By Region, From 2019-2024 ( USD Billion )
  118. Middle East Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  119. Middle East Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )
  120. Africa Checkpoint Inhibitors Market By Drug Type, From 2019-2024 ( USD Billion )
  121. Africa Checkpoint Inhibitors Market By Application, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample